Drugs / Revottack
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05644509 | Dec 2022 → Dec 2023 | neoplasm | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Revottack | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05644509 ↗ |
| Modality | Other / unclassified | “vesicular stomatitis oncolytic virus injection (Revottack)” NCT05644509 ↗ |
| Route | Intravenous | “Intravenous injection of Revottack injection” NCT05644509 ↗ |